Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$6.43 -2.9%	$5.44	$3.96 ▼ $9.85	$2.45B	0.41	2.58 million shs	1.54 million shs
CTLT Catalent	$63.48	$62.87	$57.45 ▼ $63.50	$11.52B	1.15	2.06 million shs	N/A
IONS Ionis Pharmaceuticals	$41.73 -1.5%	$36.34	$23.95 ▼ $52.34	$6.75B	0.23	1.62 million shs	1.55 million shs
PRGO Perrigo	$27.52 +0.9%	$26.71	$23.14 ▼ $30.93	$3.75B	0.45	1.44 million shs	1.08 million shs
SRPT Sarepta Therapeutics	$18.17 -4.7%	$30.98	$16.88 ▼ $154.13	$1.87B	0.45	2.24 million shs	3.08 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	-3.24%	-7.47%	+20.75%	+48.67%	-12.22%
CTLT Catalent	0.00%	0.00%	0.00%	0.00%	+10.53%
IONS Ionis Pharmaceuticals	-1.53%	-2.91%	+15.31%	+49.57%	-12.79%
PRGO Perrigo	+0.88%	+1.18%	+0.40%	+11.91%	+1.33%
SRPT Sarepta Therapeutics	-4.72%	-0.25%	-51.94%	-64.39%	-87.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHC Bausch Health Cos	3.8422 of 5 stars	1.9	4.0	0.0	4.0	2.3	3.3	0.6
CTLT Catalent	1.0652 of 5 stars	1.0	0.0	0.0	4.6	0.0	0.0	1.9
IONS Ionis Pharmaceuticals	4.6699 of 5 stars	4.4	2.0	0.0	3.0	3.4	3.3	0.6
PRGO Perrigo	4.4973 of 5 stars	2.1	2.0	4.2	3.5	2.1	1.7	2.5
SRPT Sarepta Therapeutics	4.7151 of 5 stars	4.2	2.0	0.0	4.2	2.3	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	1.83	Reduce	$7.30	13.53% Upside
CTLT Catalent	2.00	Hold	$63.50	0.03% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$58.25	39.59% Upside
PRGO Perrigo	2.25	Hold	$33.00	19.91% Upside
SRPT Sarepta Therapeutics	2.44	Hold	$58.54	222.19% Upside

Current Analyst Ratings Breakdown

Latest SRPT, PRGO, BHC, IONS, and CTLT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	SRPT Sarepta Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $28.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/25/2025	SRPT Sarepta Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
6/20/2025	SRPT Sarepta Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$123.00 ➝ $45.00
6/20/2025	SRPT Sarepta Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
6/18/2025	SRPT Sarepta Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$85.00 ➝ $40.00
6/18/2025	SRPT Sarepta Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00
6/17/2025	SRPT Sarepta Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$50.00 ➝ $25.00
6/17/2025	SRPT Sarepta Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$29.00
6/17/2025	SRPT Sarepta Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$60.00 ➝ $30.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$9.63B	0.25	$7.48 per share	0.86	($0.89) per share	-7.22
CTLT Catalent	$4.38B	2.63	$2.64 per share	24.04	$19.91 per share	3.19
IONS Ionis Pharmaceuticals	$705M	9.42	N/A	N/A	$3.73 per share	11.19
PRGO Perrigo	$4.37B	0.87	$5.10 per share	5.40	$31.66 per share	0.87
SRPT Sarepta Therapeutics	$1.90B	0.94	$2.32 per share	7.83	$15.99 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	-$46M	-$0.11	N/A	1.38	N/A	-0.41%	-540.45%	5.26%	7/30/2025 (Estimated)
CTLT Catalent	-$1.04B	-$2.26	N/A	47.02	2.69	-9.28%	-0.66%	-0.24%	N/A
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.99	N/A	-4.16%	8.93%	3.87%	8/1/2025 (Estimated)
SRPT Sarepta Therapeutics	$235.24M	-$2.69	N/A	1.66	N/A	-11.12%	-14.88%	-5.12%	8/6/2025 (Estimated)

Latest SRPT, PRGO, BHC, IONS, and CTLT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	IONS Ionis Pharmaceuticals	$0.19	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	SRPT Sarepta Therapeutics	$0.89	N/A	N/A	N/A	$530.66 million	N/A
8/1/2025	Q2 2025	PRGO Perrigo	$0.59	N/A	N/A	N/A	$1.08 billion	N/A
7/30/2025	Q2 2025	BHC Bausch Health Cos	$0.9320	N/A	N/A	N/A	$2.47 billion	N/A
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/6/2025	Q1 2025	SRPT Sarepta Therapeutics	$2.20	-$3.42	-$5.62	-$4.60	$685.75 million	$744.86 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
CTLT Catalent	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.22%	N/A	N/A	23 Years
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest SRPT, PRGO, BHC, IONS, and CTLT Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	N/A	1.35	0.97
CTLT Catalent	1.38	2.51	1.96
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
PRGO Perrigo	0.82	2.36	1.28
SRPT Sarepta Therapeutics	1.00	4.02	2.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
CTLT Catalent	N/A
IONS Ionis Pharmaceuticals	93.86%
PRGO Perrigo	95.91%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	8.05%
CTLT Catalent	0.31%
IONS Ionis Pharmaceuticals	2.60%
PRGO Perrigo	0.70%
SRPT Sarepta Therapeutics	7.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,700	370.08 million	340.29 million	Optionable
CTLT Catalent	16,900	181.51 million	180.95 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	155.02 million	Optionable
PRGO Perrigo	8,379	137.48 million	136.52 million	Optionable
SRPT Sarepta Therapeutics	1,372	98.28 million	90.71 million	Optionable

SRPT, PRGO, BHC, IONS, and CTLT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT

4 hours ago | prnewswire.com

Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

4 hours ago | theglobeandmail.com

SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

July 12 at 8:26 AM | prnewswire.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Sold by Banque Pictet & Cie SA

July 12 at 5:08 AM | marketbeat.com

Principal Financial Group Inc. Trims Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

July 12 at 3:35 AM | marketbeat.com

Lost Money on Sarepta Therapeutics, Inc.(SRPT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

July 11 at 4:22 PM | globenewswire.com

SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 11 at 4:00 PM | globenewswire.com

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

July 11 at 10:41 AM | globenewswire.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights - SRPT

July 11 at 9:00 AM | prnewswire.com

Zacks Research Has Optimistic Outlook of SRPT Q2 Earnings

July 11 at 6:42 AM | marketbeat.com

Sarepta Therapeutics Inc. Research & Ratings | SRPT | Barron's

July 11 at 5:10 AM | barrons.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SRPT

July 10 at 8:40 PM | globenewswire.com

Sarepta Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights – SRPT

July 10 at 4:55 PM | globenewswire.com

Sarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $28.00 at JPMorgan Chase & Co.

July 10 at 4:29 PM | marketbeat.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The ...

July 10 at 10:48 AM | gurufocus.com

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before August 25, 2025 to Discuss Your Rights - SRPT

July 10 at 9:00 AM | prnewswire.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, ...

July 10 at 8:21 AM | gurufocus.com

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - SRPT

July 10 at 7:44 AM | globenewswire.com

Sarepta Therapeutics: Overcoming Setbacks with Promising Long-term Potential

July 10 at 6:57 AM | tipranks.com

SRPT - Sarepta Therapeutics Inc Ownership - Morningstar

July 9 at 10:42 PM | morningstar.comM

SRPT Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. (SRPT) - Contact Kessler Topaz Meltzer & Check, LLP

July 9 at 3:51 PM | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside

SRPT, PRGO, BHC, IONS, and CTLT Company Descriptions

Bausch Health Cos NYSE:BHC

$6.43 -0.19 (-2.87%)

Closing price 07/11/2025 03:59 PM Eastern

Extended Trading

$6.42 -0.01 (-0.23%)

As of 07/11/2025 07:47 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Catalent NYSE:CTLT

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules. The Pharma and Consumer Health segment offers formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations; and oral, nasal, inhaled, and topical dose forms. This segment also provides clinical supply services through manufacturing, packaging, storage, distribution, and inventory management for small-molecule drugs, protein-based biologics, and cell and gene therapies in clinical trials; and pre-clinical screening, formulation, analytical development, and current good manufacturing practices manufacturing at clinical and commercial scale for softgel capsule, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply solutions; fill and finish operations for injectable products; and integrated development and product supply chain solutions. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was founded in 1933 and is headquartered in Somerset, New Jersey.

Ionis Pharmaceuticals NASDAQ:IONS

$41.73 -0.65 (-1.53%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$41.66 -0.07 (-0.18%)

As of 07/11/2025 07:54 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Perrigo NYSE:PRGO

$27.52 +0.25 (+0.92%)

Closing price 07/11/2025 03:58 PM Eastern

Extended Trading

$27.21 -0.31 (-1.13%)

As of 07/11/2025 07:34 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Sarepta Therapeutics NASDAQ:SRPT

$18.17 -0.90 (-4.72%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.16 -0.01 (-0.08%)

As of 07/11/2025 07:50 PM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SRPT, PRGO, BHC, IONS, and CTLT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SRPT, PRGO, BHC, IONS, and CTLT Earnings

Compare Dividends

Latest SRPT, PRGO, BHC, IONS, and CTLT Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SRPT, PRGO, BHC, IONS, and CTLT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SRPT, PRGO, BHC, IONS, and CTLT Company Descriptions

Bausch Health Cos NYSE:BHC

Catalent NYSE:CTLT

Ionis Pharmaceuticals NASDAQ:IONS

Perrigo NYSE:PRGO

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools